Drug Type Monoclonal antibody |
Synonyms anti-IL4R antibody(Shandong Boan Biotech) + [2] |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 2 | China | 19 Jul 2024 | |
Asthma | Phase 2 | China | - | |
Pruritus | Phase 2 | China | - | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | China | - | |
Sinusitis | Phase 2 | China | - | |
Urticaria | Phase 2 | China | - | |
Chronic Urticaria | Phase 1 | China | 09 Feb 2023 | |
prurigo nodularis | Phase 1 | China | 09 Feb 2023 | |
Chronic rhinosinusitis with nasal polyps | IND Approval | China | 22 Nov 2022 | |
Eczema | Preclinical | China | 18 Jul 2022 |